🔒 Premium: Once-maligned Ivermectin now on US Govt “Covid Treatment Guidelines” website.

LATEST ON BIZNEWS RADIO: Piet Viljoen’s updated guide to smart investing: Booming US dollar, stock ratings won’t last forever. Prepare accordingly.  (To listen on Spotify, click here.)


Something extraordinary is happening. As the truth emerges about what really works against Covid-19, those invested in propagating Big Pharma’s narrative are quietly recanting. Including the US Government, as BizNews community member Gail Daus-Van Wyk shared with us yesterday (see above). 

Long-vilified Ivermectin is now listed alongside four other drugs in the Covid-19 “Antiviral Therapy” section of the US Government’s National Institute of Health website. The NIH, part of the US Health Department, describes itself as “the nation’s medical research agency – making important discoveries that improve health and save lives.”

Multifacted Ivermectin earned its inventors the Nobel Prize in 2015 after its successful deployment against some of the world’s most devastating tropical diseases. The cheap drug has been used to good effect against Covid-19 by SA medics, many in poorly resourced State hospitals and clinics, who claim it made the difference between life and death for many patients. 

Despite this endorsement, SA outlawed the drug, presumably on the basis of the World Health Organisation’s March 2021 statement that Ivermectin should only be used to treat Covid-19 “within clinical trials.” On Monday, YouTube issued a one week suspension on the uploading of new material to BizNews TV because of a challenge to an August 2021 video where two local doctors and a professor discussed Ivermectin’s benefits. 

More for you to read today: 


As a Premium subscriber you are entitled to full membership of wsj.com (normal price $29 a month). Be sure to action your access through the Premium link on the BizNews website. Because of The Wall Street Journal’s credential requirements, be sure to create a password which has at least 8 characters and includes at least one letter and one number – NB it MAY NOT contain any special characters (ie #, !, @ etc). To maintain access to WSJ.com, you MUST enter our partner’s website via Biznews Premium at least once a month. A final PS, if you had previously signed up for WSJ you’ll need to clear the cookies from your device. Our helpdesk can assist –[email protected].

Visited 76 times, 1 visit(s) today